Melania Kachrimanidou

Prof. Dr. Melania Kachrimanidou

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Dairy Science
Verified
Journal Article
Closed access
GFGeorge Filioussis
George Filioussis
Melania KachrimanidouMelania Kachrimanidou
Melania Kachrimanidou
Georgios ChristodoulopoulosGeorgios Christodoulopoulos
Georgios Christodoulopoulos
MKMaria Kyritsi
Maria Kyritsi
Christos HadjichristodoulouChristos Hadjichristodoulou
Christos Hadjichristodoulou
Alex GrinbergAlex Grinberg
Alex Grinberg
We performed a survey aimed at analyzing milk samples collected from cows with mastitis for the presence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli. Single-quarter mastitic milk samples obtained from 400 cows in 23 Greek dairy herds with a history of E. coli mastitis were processed for the selective isolation of ESBL-producing E. coli. The antimicrobial susceptibility of the ESBL-producing isolates was analyzed using agar disk diffusion, and minimum inhibitory concentrations of colistin were determined by broth microdilution. We used PCR followed by DNA sequencing to characterize the β-lactamases and mcr-1 (colistin resistance) genes, and for phylotyping and multilocus sequence typing. We found a total of 89/400 (22.25%) E. coli isolates from 12/23 (52%) farms. Six isolates originating from 6 cows on a single farm were ESBL producers and were resistant to cefquinome, amoxicillin-clavulanic acid, aztreonam, ampicillin, and colistin. Five of these isolates were resistant to trimethoprim-sulfamethoxazole, and 5 to streptomycin. The 6 ESBL producers were mcr-1-positive and carried blaTEM-1 genes; 3 also carried blaCTX-M genes, and 3 carried blaSHV genes. All of the ESBL producers belonged to phylogroup A, multilocus sequence type ST666 (n = 5), or a single locus variant of ST666 (n = 1). To our knowledge, this is the first report of endemic bovine mastitis caused by mcr-1-positive, ESBL-producing E. coli. These results highlight the value of active surveillance of antimicrobial resistance not commonly tested by diagnostic laboratories for the early detection of novel resistant strains.

16 May 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
EPEvdokia Pourliotopoulou
Evdokia Pourliotopoulou
Theodoros KarampatakisTheodoros Karampatakis
Theodoros Karampatakis
Melania KachrimanidouMelania Kachrimanidou
Melania Kachrimanidou
Clostridioides difficile infection (CDI) is the leading cause of nosocomial antibiotic-associated diarrhea, and colitis, with increasing incidence and healthcare costs. Its pathogenesis is primarily driven by toxins produced by the bacterium C. difficile, Toxin A (TcdA) and Toxin B (TcdB). Certain strains produce an additional toxin, the C. difficile transferase (CDT), which further enhances the virulence and pathogenicity of C. difficile. These toxins disrupt colonic epithelial barrier integrity, and induce inflammation and cellular damage, leading to CDI symptoms. Significant progress has been made in the past decade in elucidating the molecular mechanisms of TcdA, TcdB, and CDT, which provide insights into the management of CDI and the future development of novel treatment strategies based on anti-toxin therapies. While antibiotics are common treatments, high recurrence rates necessitate alternative therapies. Bezlotoxumab, targeting TcdB, is the only available anti-toxin, yet limitations persist, prompting ongoing research. This review highlights the current knowledge of the structure and mechanism of action of C. difficile toxins and their role in disease. By comprehensively describing the toxin-mediated mechanisms, this review provides insights for the future development of novel treatment strategies and the management of CDI.

1 October 2020 in Anaerobe
Verified
Journal Article
Closed access
Melania KachrimanidouMelania Kachrimanidou
Melania Kachrimanidou
ABAmoe Baktash
Amoe Baktash
SMSymeon Metallidis
Symeon Metallidis
ΟTΟlga Tsachouridou
Οlga Tsachouridou
FNFoteini Netsika
Foteini Netsika
EKEd Kuijper
Ed Kuijper

28 February 2025 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
DMDimitra Mougiou
Dimitra Mougiou
Georgia GioulaGeorgia Gioula
Georgia Gioula
Lemonia SkouraLemonia Skoura
Lemonia Skoura
Cleo AnastassopoulouCleo Anastassopoulou
Cleo Anastassopoulou
Melania KachrimanidouMelania Kachrimanidou
Melania Kachrimanidou
Clostridioides difficile (C. difficile) is a significant healthcare-associated pathogen that is predominantly caused by antibiotic-induced microbiota disturbance. Antibiotics decrease microbial diversity, resulting in C. difficile colonization and infection. Clostridium difficile infection (CDI) manifests through toxins A and B, causing diarrhea and colitis. Antibiotic usage, old age, and hospitalization are significant risk factors. A healthy gut microbiota, which is dominated by Firmicutes and Bacteroidetes, provides colonization resistance to C. difficile due to competition for nutrients, creating inhibitory substances and stimulating the immune response. Antibiotic-induced dysbiosis decreases resistance, allowing C. difficile spores to transform into vegetative forms. Patients with CDI have decreased gut microbiota diversity, with a decrease in beneficial bacteria, including Bacteroidetes, Prevotella, and Bifidobacterium, and a rise in harmful bacteria like Clostridioides and Lactobacillus. This disparity worsens the infection’s symptoms and complicates therapy. Fecal Microbiota Transplantation (FMT) has emerged as a potential therapy for recurrent CDI by restoring gut microbiota diversity and function. Comprehending the connection between gut microbiota and CDI pathogenesis is critical for establishing effective preventive and treatment plans. Maintaining a healthy gut microbiota through careful antibiotic use and therapeutic options such as FMT can help in the management and prevention of CDI.

1 April 2013 in American Journal of Infection Control
Verified
Journal Article
Closed access
AVAnna Vardi
Anna Vardi
ASAntonia Sirigou
Antonia Sirigou
CLChrysavgi Lalayanni
Chrysavgi Lalayanni
Melania KachrimanidouMelania Kachrimanidou
Melania Kachrimanidou
PKPanayiotis Kaloyannidis
Panayiotis Kaloyannidis
DSDamianos Sotiropoulos
Damianos Sotiropoulos

16 February 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
SASotiris Alexiou
Sotiris Alexiou
Anastasia DiakouAnastasia Diakou
Anastasia Diakou
Melania KachrimanidouMelania Kachrimanidou
Melania Kachrimanidou
Clostridioides difficile is the leading cause of antibiotic-associated diarrhea in hospitalized patients. In recent years, the incidence of C. difficile infection (CDI) has increased globally, with a notable rise in community-associated CDI (CA-CDI). The presence of the microorganism in animals, the environment, and food suggests that these sources may contribute to the spread of the infection in the community. This review applies a One Health approach, integrating human, animal, and environmental health, to provide a comprehensive strategy for understanding and managing this pathogen. Findings reveal the widespread dissemination of C. difficile in animals, the environment, and food. The predominant PCR ribotypes identified were RTs 078 and 014/020, followed by RTs 126, 001, 002, 009, 010, and 033. C. difficile strains exhibited resistance to multiple antimicrobial agents, including clindamycin, erythromycin, fluoroquinolones, cephalosporins, and tetracyclines. Discriminative typing methods, such as whole-genome sequencing, revealed clonal relationships between C. difficile strains from humans and animals, indicating either direct transmission or a common environmental source of infection. The high genetic similarity between isolates from the environment and humans indicates potential environmental contamination. Additionally, clusters of C. difficile strains found in food and humans indicate a possible foodborne transmission route. This review summarizes the current knowledge on the role of Clostridioides difficile within the One Health framework.